



US 20210292299A1

(19) **United States**(12) **Patent Application Publication**
Gray et al.(10) **Pub. No.: US 2021/0292299 A1**(43) **Pub. Date: Sep. 23, 2021**(54) **TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF**(71) Applicant: **Dana-Farber Cancer Institute, Inc.**,
Boston, MA (US)(72) Inventors: **Nathanael S. Gray**, Boston, MA (US);
Fleur M. Ferguson, Boston, MA (US);
Zainab M. Doctor, Brookline, MA (US)(73) Assignee: **Dana-Farber Cancer Institute, Inc.**,
Boston, MA (US)(21) Appl. No.: **17/255,647**(22) PCT Filed: **Jun. 24, 2019**(86) PCT No.: **PCT/US2019/038677**

§ 371 (c)(1),

(2) Date: **Dec. 23, 2020****Related U.S. Application Data**

(60) Provisional application No. 62/689,551, filed on Jun. 25, 2018.





Publication Classification(51) **Int. Cl.****C07D 401/12** (2006.01)**C07D 231/40** (2006.01)**C07D 495/04** (2006.01)**C07D 403/12** (2006.01)**C07D 417/12** (2006.01)**A61K 45/06** (2006.01)(52) **U.S. Cl.**CPC **C07D 401/12** (2013.01); **C07D 231/40**
(2013.01); **A61K 45/06** (2013.01); **C07D**
403/12 (2013.01); **C07D 417/12** (2013.01);
C07D 495/04 (2013.01)

(57)

ABSTRACT

Provided herein are compounds of Formula (I') or (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers (e.g., carcinoma); lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer)), metabolic disorders (e.g., diabetes), autoimmune diseases, and neurological diseases (e.g., Alzheimer's disease, gliosis, spinal cord injury)) in a subject, as well as for male contraception (e.g., reducing or inhibiting spermatogenesis, or reducing the rate of male fertility in a healthy fertile male subject). Provided are methods of inhibiting a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18) in a subject.

(I')

**FMF-04-0159-2****FMF-05-032-1****FMF-05-118-1****FMF-04-107-2**